spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Prolia 

 HSMN NewsFeed - 9 Dec 2021
Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia(R) and Xgeva(R)
Biopharmaceuticals Generics Licensing
 HSMN NewsFeed - 11 Feb 2020
Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jan 2020
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Feb 2018
UNITY Biotechnology Adds Accomplished R&D Leader David L. Lacey, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Sep 2016
Assembly Biosciences Announces Key Additions to Microbiome Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Feb 2016
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 11 Jan 2016
ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 19 Feb 2015
ZS Pharma Hires Key Medical Affairs and Commercial Executives
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2013
Amgen Outlines Long-Term Strategy
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2011
FDA Approves New Indications for Prolia(R) (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Aug 2011
Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Dec 2010
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2010
FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2010
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Apr 2010
Amgen Appoints Robert A. Bradway President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2010
FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Feb 2010
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2009
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Oct 2009
Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Sep 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2009
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.